Louis Gaboury, M.D., Ph.D., F.R.C.P.(C), F.C.A.P.
Awards & Honours
- Teaching Excellence Award, Université de Montréal, 1997
- Télésphore Parizeau Award, 1978
- Postdoctoral training in molecular biology with Paul Jolicoeur, Institut de recherches cliniques de Montréal, 1988-1991
- Postdoctoral training with Connie Eaves, Terry Fox Laboratory, BC Cancer Research Centre, 1984-1988
- Ph.D. in experimental pathology, University of British Columbia, 1988
- Post-graduate diploma in anatomic-pathology, Université de Montréal, 1983
- Doctor of Medicine, Université de Montréal, 1978
- Canadian Institutes of Health Research
- Québec Consortium for Drug Discovery
- Roche Canada
Louis Gaboury received his doctoral degree in medicine from the Université de Montréal in 1978. After completing a multidisciplinary medical internship at Hôtel-Dieu de Montréal Hospital, he undertook graduate studies in anatomic-pathology. Once admitted as anatomical pathologist by the Collège des médecins du Québec, the Royal College of Physicians and Surgeons of Canada and the College of American Pathologists, he pursued further training in experimental pathology at the BC Cancer Centre in Vancouver. He then completed a second postdoctoral fellowship in Molecular Biology at the Institut de recherches cliniques de Montréal.
He started his academic career at the Université de Montréal as Assistant Professor in 1991. At the same time, he joined the department of pathology at Hôtel-Dieu de Montréal Hospital where he established a Molecular Diagnosis laboratory while continuing to practice medical and surgical pathology. His research at the time sought to analyse point mutations arising in hereditary cancers such as RET mutations in MEN-2 A & MEN-2B syndrome and BRCA-1 & BRCA-2 mutations in familial breast cancers. More recently, he set up the assays for molecular testing for colon cancer arising in the context of defects in Mismatch Repair Genes (MSH-2, MLH-1 and MSH-6).
Dr. Gaboury became interested in developing molecular tools to assay the overexpression of the HER-2 oncogene. He was able to establish the FISH assay to determine the presence or absence of gene amplification in his laboratory. Because of his expertise, he was appointed member of the National Standards Committee that establishes Canadian guidelines for HER-2 immunhistochemistry assays.
His interest in breast pathology led him to study the human myoepithleial cell lineage during breast development and during breast cancer progression. His research in this area has led to the characterization of the human myoepithlial cell during breast development as well as in the normal and diseased breast tissues.
Since 2003, Dr. Gaboury has been collaborating with Thallion Pharmaceutical (formerly Caprion) in three major projects aimed at the proteomic characterization of three cancers, namely breast, lung, and prostate.
In 2006, Dr. Gaboury was recruited by IRIC to direct its histology core facility. In 2009, he was named Principal Investigator at IRIC where he continues to provide high quality histological services and consultation, and to develop new methods and tools, such as telepathology. Dr. Gaboury divides his time between research, teaching and his clinical work which focuses on medical and surgical pathology, and molecular pathology.